Redeye initiates coverage of Herantis Pharma, a biotech developing drug candidates in the difficult area of Parkinson’s, an area with great potential to improve the standard of care. The case hinges on blockbuster potential in this expanding market, supported by experienced management, institutional ownership and a prospective licensing deal. While the share trades close to fair value, longer-term upside is compelling.